Previous 10 | Next 10 |
– To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized – – Anticipated fourth quarter m...
Section 32 Raises $740 Million Venture Fund --Firm's Fourth Fund Maintains its Strategy of Investing in Companies at the Intersection of Technology and Healthcare; Firm Adds Nina Labatt as Chief Operating Officer and Chief Financial Officer-- PR Newswire SAN DIEGO ...
VIR's multibillion market cap is based on its potential to treat emerging forms of the coronavirus. Effective vaccines, reducing trend of the pandemic etc. work against Vir. I will avoid for now. For further details see: Vir Biotechnology: Still Valued On Potential, Whic...
GlaxoSmithKline (NYSE:GSK) is scheduled to announce Q3 earnings results on Wednesday, October 27th, before market open. The consensus EPS Estimate is $0.81 (+224.0% Y/Y) and the consensus Revenue Estimate is $11.96B (+38.3% Y/Y). Over the last 2 years, GSK has beaten EPS estimates 88% of the ...
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021. The update will be provided via...
SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American A...
SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwright 2 nd Annual Hepatitis B Virus (HBV) Conference on Wednesday, Oct. 13, at 9:30 a.m. P...
Welcome to the "Merck Cures COVID!" edition of Hot Stocks. Of course, the drug maker didn't actually cure the disease. But it did release blockbuster clinical-trial data for an anti-COVID pill that contributed to an overall Wall Street rally. Many segments of the market took the MRK anno...
Gainers: Progenity (NASDAQ:PROG) +29%, Biomerica (NASDAQ:BMRA) +28%, Atea Pharmaceuticals (NASDAQ:AVIR) +19%, Silverback Therapeutics (NASDAQ:SBTX) +13%, Codexis (NASDAQ:CDXS) +12%. Losers: Omeros (NASDAQ:OMER) -41%, Adagio Therapeut...
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim 2 nd Annual Vaccine & Infectious Disease Day Conference on Wednesday, Oct. 6, at 11:3...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...